Nutraceuticals and mitochondrial oxidative stress: bridging the gap in the management of bronchial asthma

Environ Sci Pollut Res Int. 2022 Sep;29(42):62733-62754. doi: 10.1007/s11356-022-21454-w. Epub 2022 Jul 7.

Abstract

Asthma is a chronic inflammatory disease primarily characterized by inflammation and reversible bronchoconstriction. It is currently one of the leading causes of morbidity and mortality in the world. Oxidative stress further complicates the pathology of the disease. The current treatment strategies for asthma mainly involve the use of anti-inflammatory agents and bronchodilators. However, long-term usage of such medications is associated with severe adverse effects and complications. Hence, there is an urgent need to develop newer, novel, and safe treatment modalities for the management of asthma. This has therefore prompted further investigations and detailed research to identify and develop novel therapeutic interventions from potent untapped resources. This review focuses on the significance of oxidative stressors that are primarily derived from both mitochondrial and non-mitochondrial sources in initiating the clinical features of asthma. The review also discusses the biological scavenging system of the body and factors that may lead to its malfunction which could result in altered states. Furthermore, the review provides a detailed insight into the therapeutic role of nutraceuticals as an effective strategy to attenuate the deleterious effects of oxidative stress and may be used in the mitigation of the cardinal features of bronchial asthma.

Keywords: Asthma; Inflammation; Mitochondria; Nutraceuticals; Oxidative stress; Therapeutics.

Publication types

  • Review

MeSH terms

  • Asthma* / etiology
  • Bronchodilator Agents* / pharmacology
  • Bronchodilator Agents* / therapeutic use
  • Dietary Supplements
  • Humans
  • Oxidation-Reduction
  • Oxidative Stress

Substances

  • Bronchodilator Agents